Dataset from A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008708
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this study is to evaluate the effects of filgotinib versus placebo
for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the
percentage of participants achieving an American College of Rheumatology 20% improvement
response (ACR20) at Week 12.
创建时间：
2025-09-01
